Literature DB >> 26414731

Inflammation: a possible mechanism for a causative role of hyperuricemia/gout in cardiovascular disease.

F Perez-Ruiz1, M A Becker2.   

Abstract

Hyperuricemia and gout are independent risk factors associated with the development of hypertension, metabolic syndrome, vascular damage, and renal disease. Whether these risk factors are causally related to these important chronic co-morbidities remains uncertain, but inflammation may provide a mechanistic explanation. Hyperuricemia and gout negatively affect vascular function by exerting pro-oxidant effects and by decreasing nitric oxide bioavailability, thus inducing inflammation and endothelial dysfunction, which may promote hypertension, metabolic syndrome, and cardiovascular (CV) disease. This paper presents and discusses current understanding of the diverse influences promoting hyperuricemia and gout and the basis of acute and chronic hyperuricemia/gout-related inflammation. This review is based on a PubMed/Embase database search for articles on hyperuricemia and its impact on cardiovascular and renal function.

Entities:  

Keywords:  Cardiovascular disease; Gout; Hyperuricemia; Inflammation

Mesh:

Year:  2015        PMID: 26414731     DOI: 10.1185/03007995.2015.1087980

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  17 in total

1.  Hyperuricemia is associated with an increased prevalence of paroxysmal atrial fibrillation in patients with type 2 diabetes referred for clinically indicated 24-h Holter monitoring.

Authors:  A Mantovani; R Rigolon; A Civettini; B Bolzan; G Morani; S Bonapace; C Dugo; G Zoppini; E Bonora; G Targher
Journal:  J Endocrinol Invest       Date:  2017-07-15       Impact factor: 4.256

2.  Longitudinal transition trajectory of gouty arthritis and its comorbidities: a population-based study.

Authors:  Chien-Fang Huang; Ju-Chi Liu; Hui-Chuan Huang; Shao-Yuan Chuang; Chang-I Chen; Kuan-Chia Lin
Journal:  Rheumatol Int       Date:  2016-12-21       Impact factor: 2.631

3.  Effects of febuxostat on insulin resistance and expression of high-sensitivity C-reactive protein in patients with primary gout.

Authors:  Juan Meng; Yanchun Li; Xiaoxu Yuan; Yuewu Lu
Journal:  Rheumatol Int       Date:  2016-11-23       Impact factor: 2.631

4.  A case-control study to investigate association between serum uric acid levels and paroxysmal atrial fibrillation.

Authors:  Xia Zhong; Huachen Jiao; Dongsheng Zhao; Jing Teng
Journal:  Sci Rep       Date:  2022-06-20       Impact factor: 4.996

5.  Impaired arterial responsiveness in untreated gout patients compared with healthy non-gout controls: association with serum urate and C-reactive protein.

Authors:  Svetlana Krasnokutsky; Aaron Garza Romero; Daisy Bang; Virginia C Pike; Binita Shah; Talia F Igel; Irina Dektiarev; Yu Guo; Judy Zhong; Stuart D Katz; Michael H Pillinger
Journal:  Clin Rheumatol       Date:  2018-02-15       Impact factor: 2.980

6.  The risk of polymyalgia rheumatica in older adults with gout: a Medicare claims study.

Authors:  Jasvinder A Singh; John D Cleveland
Journal:  Rheumatol Adv Pract       Date:  2018-06-20

Review 7.  "TRP inflammation" relationship in cardiovascular system.

Authors:  Tomohiro Numata; Kiriko Takahashi; Ryuji Inoue
Journal:  Semin Immunopathol       Date:  2015-10-19       Impact factor: 9.623

8.  Ghrelin suppresses inflammation in HUVECs by inhibiting ubiquitin-mediated uncoupling protein 2 degradation.

Authors:  Ruolan Zhang
Journal:  Int J Mol Med       Date:  2017-05-05       Impact factor: 4.101

Review 9.  Recent advances on uric acid transporters.

Authors:  Liuqing Xu; Yingfeng Shi; Shougang Zhuang; Na Liu
Journal:  Oncotarget       Date:  2017-08-10

10.  Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study.

Authors:  Hisashi Yamanaka; Shigenori Tamaki; Yumiko Ide; Hyeteko Kim; Kouichi Inoue; Masayuki Sugimoto; Yuji Hidaka; Atsuo Taniguchi; Shin Fujimori; Tetsuya Yamamoto
Journal:  Ann Rheum Dis       Date:  2017-11-04       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.